InvestorsObserver
Sign Up Login

CMRA Comera Life Sciences Holdings In

$2.90 $0.04 (1.40%)
Add to Watchlist Compare
Overall

CMRA Stock Analysis Overview

What this means: Comera Life Sciences Holdings In (CMRA) gets a very poor rank from InvestorsObserver. Our comprehensive analysis of fundamental and technical factors gives CMRA a rank of 14. Our methodology considers analysis of the company's financial situation and how it has traded recently. CMRA rank of 14 means that it ranks below 86% of stocks.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

View Sample Report
Fundamental PREMIUM

CMRA Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

Short-Term Technical PREMIUM

CMRA Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

Long-Term Technical PREMIUM

CMRA Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

Analyst Ranking PREMIUM

CMRA Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

Valuation PREMIUM

CMRA Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

Stock Sentiment PREMIUM

CMRA Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

CMRA Stock Analysis Overview

What this means: Comera Life Sciences Holdings In (CMRA) gets a very poor rank from InvestorsObserver. Our comprehensive analysis of fundamental and technical factors gives CMRA a rank of 14. Our methodology considers analysis of the company's financial situation and how it has traded recently. CMRA rank of 14 means that it ranks below 86% of stocks.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

Create a FREE account to see full CMRA report

CMRA Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

CMRA Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

CMRA Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

CMRA Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

CMRA Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

CMRA Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

Comera Life Sciences Holdings In (CMRA) Analyst Forecast

CMRA Price, Volume, Earnings, and Dividend Date

  • Last Price $2.90
  • Previous Close $2.86
  • Change $0.04
  • Open $2.86
  • Volume 800
  • Avg. Volume (100-day) 0
  • Market Cap 55,352,837
  • Days Range 2.86 - 2.9
  • 52-week Range 1.11 - 11.44
  • Dividend Yield —
  • Ex. Dividend Date —
  • P-E —
  • EPS —
  • Earnings Date —
  • Sector Healthcare
  • Industry Biotechnology
  • Avg. Analyst Rec. Premium
  • Beta 0.556
  • PEG Ratio —

Comera Life Sciences Holdings In (CMRA) Company Description

Comera Life Sciences Holdings Inc is a pre-clinical biotechnology company dedicated to promoting a formulation science and technology to transform essential biologic medicines from intravenous to subcutaneous forms. Comera's internal portfolio of proprietary techniques known as the SQore platform is designed to potentially transform essential biologic medicines from intravenous (IV) to subcutaneous (SQ) forms, and optimize current versions of subcutaneous biologics, and produce biosimilar versions of existing subcutaneous products. It also collaborates with pharmaceutical and biotechnology companies, applying the SQore platform to the Company's partners' biologic medicines to deliver enhanced formulations that facilitate self-injectable care.

Comera Life Sciences Holdings In (CMRA) Stock Chart

View Interactive CMRA chart

My Watchlists

Follow Your Favorite Stocks

Top Stocks in Biotechnology

Company Price
Trevi Therapeutics Inc (TRVI) (TRVI) $3.91
Savara Inc (SVRA) (SVRA) $1.74
Arcutis Biotherapeutics Inc (ARQT) (ARQT) $25.15
Axsome Thera (AXSM) (AXSM) $43.44
G1 Therapeutics Inc (GTHX) (GTHX) $13.01
Liquidia Corp (LQDA) (LQDA) $5.37
Pharvaris N.V. (PHVS) (PHVS) $19.00
Pliant Therapeutics Inc (PLRX) (PLRX) $18.91
Nucana Plc ADR (NCNA) (NCNA) $1.81
Selecta Biosciences (SELB) (SELB) $2.36